CATALYST PHARMACEUTICALS, INC.: 10-Q filed 2016-05-10
What CATALYST PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-05-10 (fiscal Q1 2016): 28 published measures, 57 facts as tagged in accession 0001193125-16-585609.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-05-10
- Fiscal period
- fiscal Q1 2016
- Accession
- 0001193125-16-585609 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 53,666,043 | USD | |
| At 2015-12-31 | 60,101,570 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 3,129,265 | USD | |
| At 2015-12-31 | 4,625,259 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 50,536,778 | USD | |
| At 2015-12-31 | 55,476,311 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 22,227,962 | USD | |
| At 2015-12-31 | 28,235,016 | USD | |
| At 2015-03-31 | 41,323,435 | USD | |
| At 2014-12-31 | 9,096,778 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -5,386,237 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -5,410,259 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 7,910 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 0 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 0 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | -95,461,855 | USD | |
| At 2015-12-31 | -90,075,618 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 0 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 0 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 178,351 | USD | |
| At 2015-12-31 | 191,549 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 457,969 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 314,451 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -6,237,536 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -4,291,915 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 53,478,804 | USD | |
| At 2015-12-31 | 59,901,133 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 2,663,787 | USD | |
| At 2015-12-31 | 3,440,603 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 1,251,473 | USD | |
| At 2015-12-31 | 1,794,127 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 6,237,536 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 4,291,915 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 3,546,391 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 2,349,552 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 82,870,649 | shares | |
| At 2015-12-31 | 82,850,619 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 145,915,762 | USD | |
| At 2015-12-31 | 145,469,078 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 261,623 | USD | |
| At 2015-12-31 | 261,623 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 83,272 | USD | |
| At 2015-12-31 | 70,074 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 1,412,314 | USD | |
| At 2015-12-31 | 1,646,476 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 1,023,892 | USD | |
| At 2015-12-31 | 1,504,738 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -5,386,237 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -5,410,259 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 2,691,145 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,942,363 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 13,198 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 8,148 | USD | 90 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 117,943 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 61,934 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -542,654 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -763,695 | USD | 90 |
Inspect the source
- Entity
- CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
- Captured
- SEC response SHA-256
7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))